JP5730820B2 - Vip断片および使用の方法 - Google Patents
Vip断片および使用の方法 Download PDFInfo
- Publication number
- JP5730820B2 JP5730820B2 JP2012133977A JP2012133977A JP5730820B2 JP 5730820 B2 JP5730820 B2 JP 5730820B2 JP 2012133977 A JP2012133977 A JP 2012133977A JP 2012133977 A JP2012133977 A JP 2012133977A JP 5730820 B2 JP5730820 B2 JP 5730820B2
- Authority
- JP
- Japan
- Prior art keywords
- vip
- seq
- myocardial fibrosis
- treatment
- fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title description 44
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims description 889
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims description 793
- 206010028594 Myocardial fibrosis Diseases 0.000 claims description 70
- 239000000203 mixture Substances 0.000 claims description 65
- 238000011282 treatment Methods 0.000 claims description 43
- 230000001225 therapeutic effect Effects 0.000 claims description 33
- 206010016654 Fibrosis Diseases 0.000 claims description 25
- 206010020772 Hypertension Diseases 0.000 claims description 25
- 230000004761 fibrosis Effects 0.000 claims description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- 108010051789 vasoactive intestinal peptide (6-28) Proteins 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 238000011321 prophylaxis Methods 0.000 claims description 18
- 230000000069 prophylactic effect Effects 0.000 claims description 15
- 230000036772 blood pressure Effects 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 239000013543 active substance Substances 0.000 claims description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 5
- 238000007918 intramuscular administration Methods 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 775
- 208000024891 symptom Diseases 0.000 description 34
- 239000012634 fragment Substances 0.000 description 24
- 150000003839 salts Chemical class 0.000 description 20
- 238000006467 substitution reaction Methods 0.000 description 20
- 230000037213 diet Effects 0.000 description 18
- 235000005911 diet Nutrition 0.000 description 18
- DRLDAGKWYRHQAE-RLUUKXCJSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1,4-diamino-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]pentanediamide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 DRLDAGKWYRHQAE-RLUUKXCJSA-N 0.000 description 16
- 108010043936 vasoactive intestinal peptide (10-28) Proteins 0.000 description 16
- 206010019280 Heart failures Diseases 0.000 description 13
- 125000000539 amino acid group Chemical group 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 230000035488 systolic blood pressure Effects 0.000 description 11
- 108010082634 vasoactive intestinal peptide (4-11) Proteins 0.000 description 11
- 108010060353 vasoactive intestinal peptide (6-23) Proteins 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- 238000011706 wistar kyoto rat Methods 0.000 description 10
- SRYFTJDITQLOGY-GBGZRFFXSA-N (2s)-2-[[(2s,3r)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s)-2-[[(2s,3r)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino] Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CN=CN1 SRYFTJDITQLOGY-GBGZRFFXSA-N 0.000 description 9
- 206010007559 Cardiac failure congestive Diseases 0.000 description 9
- 108010080329 vasoactive intestinal peptide (1-12) Proteins 0.000 description 9
- 208000009525 Myocarditis Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000002206 pro-fibrotic effect Effects 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
- 208000031229 Cardiomyopathies Diseases 0.000 description 4
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 4
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 4
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
- 229960000975 daunorubicin Drugs 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 235000015598 salt intake Nutrition 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 3
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000011382 collagen catabolic process Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 208000028591 pheochromocytoma Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000002592 echocardiography Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- -1 V P (6-24) Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Description
心筋線維症の4つの動物モデルを使用した(Australian Animal Resources(オーストラリア、西オーストラリア、パース)から入手した動物):
i)高塩分食事を与えたWKYラット
ii)高塩分食事を与え、およびL−NAME(ω−モノメチル−ニトロ−L−アルギニン、Sigma Chemical Co.)を10mg/kg/dayで飲料水により与えたWKYラット
iii)ストレプトゾトシン注入(60mg/kg)により糖尿病を誘導したWKYラット
iv)4週間2.2%塩分食事を与えたSHRラット。
VIP(6−16)、VIP(6−20)およびVIP(6−24)注入が、既存の線維症の退行ならびに線維症の進行の阻止を引き起こすかどうかを決定するために、2つの群の研究を行った。高塩分食事またはL−NAME(10mg/kg/day)を添加した高塩分食事およびVIP(6−16)、VIP(6−20)およびVIP(6−24)(5pmol/kg/min)の何れかまたはベヒクルコントロール注入で4週間処理した後に、無処置の14週齢WKYラットにおける心筋線維症の程度を、18週齢WKYラットにおける線維症の程度と比較した(図2参照)。
VIPおよび断片が血圧を制御することに有効であるかどうかを決定するため、自然発症高血圧ラット(SHR)を、テールカフ脈波検査(tail cuff plethysmography)による血圧測定に慣れさせ、4週間の2.2%塩分食事を施した。
Claims (18)
- VIP(6−12)(配列番号68)、VIP(6−16)(配列番号72)、VIP(6−20)(配列番号76)およびVIP(6−24)(配列番号80)から成る群から選択されるペプチド。
- 請求項1に記載の1以上のペプチドを含む組成物。
- VIP(6−12)(配列番号68)、VIP(6−16)(配列番号72)、VIP(6−20)(配列番号76)およびVIP(6−24)(配列番号80)から成る群から選択される1以上のペプチドを含む、心筋線維症の予防的または治療的な処置のための組成物。
- VIP(6−20)(配列番号76)、VIP(6−24)(配列番号80)およびVIP(6−28)(配列番号84)から成る群から選択される1以上のペプチドを含む、高血圧の予防的または治療的な処置のための組成物。
- 医薬的に許容可能な担体とともに投与される、請求項2から4の何れか1項に記載の組成物。
- 心血管性症状の治療に有用な1以上のその他の活性薬剤とともに投与される、請求項2から5の何れか1項に記載の組成物。
- 経口、静脈内、筋肉内、または表皮下の経路による投与のために処方される、請求項2から6の何れか1項に記載の組成物。
- 心筋線維症の治療的または予防的な処置のための医薬の製造のための、VIP(6−12)(配列番号68)、VIP(6−16)(配列番号72)、VIP(6−20)(配列番号76)およびVIP(6−24)(配列番号80)から成る群から選択されるペプチドの使用。
- 前記医薬が、確立した心筋線維症の進行を阻止または鈍化する、請求項8に記載の使用。
- 前記医薬が、確立した線維症の程度を減少させる、請求項8に記載の使用。
- 請求項8に記載の使用であって、前記医薬が、線維症の発症を阻止または鈍化する使用。
- 血圧を降下させるための医薬の製造のための、VIP(6−20)(配列番号76)、VIP(6−24)(配列番号80)およびVIP(6−28)(配列番号84)から成る群から選択されるペプチドの使用。
- 被験体における高血圧の治療的または予防的な処置のための医薬の製造のための、VIP(6−20)(配列番号76)、VIP(6−24)(配列番号80)およびVIP(6−28)(配列番号84)から成る群から選択されるペプチドの使用。
- 請求項13に記載の使用であって、前記被験体が、心筋線維症を有する使用。
- 前記医薬が、心血管性症状の治療に有用な1以上のその他の活性薬剤をさらに含む、請求項8から14の何れか1項に記載の使用。
- 前記医薬が、経口、静脈内、筋肉内、または表皮下の経路による投与に適している、請求項8から15の何れか1項に記載の使用。
- 心筋線維症および高血圧の予防的または治療的な処置のための、VIP(6−20)(配列番号76)およびVIP(6−24)(配列番号80)から成る群から選択される1以上のペプチドを含む組成物。
- 心筋線維症および高血圧の治療的または予防的な処置のための医薬の製造のための、VIP(6−20)(配列番号76)およびVIP(6−24)(配列番号80)から成る群から選択されるペプチドの使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005906947 | 2005-12-09 | ||
AU2005906947A AU2005906947A0 (en) | 2005-12-09 | VIP fragments and methods of use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008543613A Division JP5449778B2 (ja) | 2005-12-09 | 2006-12-08 | Vip断片および使用の方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013269991A Division JP5847793B2 (ja) | 2005-12-09 | 2013-12-26 | Vip断片および使用の方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012229222A JP2012229222A (ja) | 2012-11-22 |
JP5730820B2 true JP5730820B2 (ja) | 2015-06-10 |
Family
ID=38122420
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008543613A Active JP5449778B2 (ja) | 2005-12-09 | 2006-12-08 | Vip断片および使用の方法 |
JP2012133977A Active JP5730820B2 (ja) | 2005-12-09 | 2012-06-13 | Vip断片および使用の方法 |
JP2013269991A Active JP5847793B2 (ja) | 2005-12-09 | 2013-12-26 | Vip断片および使用の方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008543613A Active JP5449778B2 (ja) | 2005-12-09 | 2006-12-08 | Vip断片および使用の方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013269991A Active JP5847793B2 (ja) | 2005-12-09 | 2013-12-26 | Vip断片および使用の方法 |
Country Status (20)
Country | Link |
---|---|
US (4) | US8470778B2 (ja) |
EP (2) | EP2783697B1 (ja) |
JP (3) | JP5449778B2 (ja) |
KR (2) | KR101404561B1 (ja) |
CN (2) | CN101325964B (ja) |
AR (2) | AR058308A1 (ja) |
AU (1) | AU2006322656B2 (ja) |
BR (1) | BRPI0620566B8 (ja) |
CA (2) | CA2632581C (ja) |
DK (2) | DK1976548T3 (ja) |
ES (2) | ES2621864T3 (ja) |
HK (1) | HK1122746A1 (ja) |
IL (3) | IL192046A (ja) |
NZ (4) | NZ597677A (ja) |
PL (1) | PL1976548T3 (ja) |
PT (1) | PT1976548E (ja) |
RU (1) | RU2466738C2 (ja) |
TW (1) | TWI402273B (ja) |
WO (1) | WO2007065226A1 (ja) |
ZA (1) | ZA200805837B (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005120545A1 (en) * | 2004-06-11 | 2005-12-22 | Vectus Biosystems Limited | Compositions and methods for treatment of cardiovascular disease |
ES2638792T3 (es) * | 2005-07-28 | 2017-10-24 | Carbon Sink Inc. | Eliminación de dióxido de carbono del aire |
NZ597677A (en) | 2005-12-09 | 2013-05-31 | Vectus Biosystems Ltd | Vip fragments and methods of use |
US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
WO2007073486A2 (en) | 2005-12-20 | 2007-06-28 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
EP2926825A1 (en) | 2008-06-27 | 2015-10-07 | Duke University | Therapeutic agents comprising elastin-like peptides |
JP2012505835A (ja) * | 2008-10-17 | 2012-03-08 | ヴェクタス バイオシステムズ ピーティーワイ リミテッド | 腎障害の治療のための組成物および方法 |
CN101434649B (zh) * | 2008-12-12 | 2012-04-25 | 余榕捷 | 一种环七肽及其制备方法和应用 |
RU2536223C2 (ru) * | 2009-04-02 | 2014-12-20 | Вектус Байосистемс Пти Лтд | Композиции и способы для лечения фиброза аорты |
KR101887009B1 (ko) | 2009-08-14 | 2018-08-09 | 파세비오 파마수티컬스 인코포레이티드 | 변형된 혈관활성 장 펩티드 |
US9561262B2 (en) | 2011-06-06 | 2017-02-07 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
RU2635564C2 (ru) * | 2013-09-17 | 2017-11-14 | Вектус Байосистемс Лимитед | Композиция для лечения гипертензии и/или фиброза |
US9375638B2 (en) * | 2014-01-02 | 2016-06-28 | Lloyd A. Weaver | Game console switch box |
WO2015172046A1 (en) | 2014-05-08 | 2015-11-12 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating cystic fibrosis |
JP6824888B2 (ja) * | 2015-02-09 | 2021-02-03 | フェーズバイオ ファーマシューティカルズ,インコーポレイテッド | 筋肉の疾患および障害を治療するための方法および組成物 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3862927A (en) * | 1973-02-26 | 1975-01-28 | Sami I Said | Process for preparation of vasoactive intestinal peptide |
US4016258A (en) * | 1975-08-05 | 1977-04-05 | Said Sami I | Vasoactive intestinal peptide from fowl |
US4237046A (en) * | 1979-04-27 | 1980-12-02 | Miklos Bodanszky | Polypeptides and methods of preparation |
GB8427651D0 (en) * | 1984-11-01 | 1984-12-05 | Beecham Group Plc | Compounds |
NZ221440A (en) * | 1986-08-20 | 1991-11-26 | Genetic Systems Corp | Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections |
US5972883A (en) * | 1993-03-16 | 1999-10-26 | Yeda Research And Development Co. Ltd. | Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof |
US5808037A (en) * | 1995-09-15 | 1998-09-15 | Ramareddy Venkata Guntaka | Oligomers which inhibit expression of collagen genes |
US20020115609A1 (en) * | 1997-07-14 | 2002-08-22 | Hayat Onyuksel | Materials and methods for making improved micelle compositions |
US5892162A (en) * | 1997-11-18 | 1999-04-06 | Southwest Research Institute | Apparatus and method for inspection of pipes and tubes using guided wave probe |
EP1244455B1 (en) * | 1999-10-29 | 2009-07-22 | Nitromed, Inc. | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
ES2347137T3 (es) * | 2000-10-20 | 2010-10-26 | Amylin Pharmaceuticals, Inc. | Tratamiento de miocardio hibernante y cardiomiopatia diabetica con un peptido gpl-1. |
AU2002220720B2 (en) * | 2000-11-28 | 2006-09-14 | Mondobiotech Ag | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension |
US6911430B2 (en) * | 2003-10-01 | 2005-06-28 | Vipogen, Llc | Compositions and methods for treating ileus |
EP1753780B1 (en) * | 2004-05-21 | 2008-03-19 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
WO2005112897A2 (en) * | 2004-05-21 | 2005-12-01 | Accu-Break Technologies, Inc. | Immediate release pharmaceutical tablets with height greater than width |
WO2005120545A1 (en) * | 2004-06-11 | 2005-12-22 | Vectus Biosystems Limited | Compositions and methods for treatment of cardiovascular disease |
NZ597677A (en) * | 2005-12-09 | 2013-05-31 | Vectus Biosystems Ltd | Vip fragments and methods of use |
WO2008073146A2 (en) * | 2006-07-06 | 2008-06-19 | University Of Wyoming | Method and apparatus for pyrolysis-induced cleavage in peptides and proteins |
JP2012505835A (ja) * | 2008-10-17 | 2012-03-08 | ヴェクタス バイオシステムズ ピーティーワイ リミテッド | 腎障害の治療のための組成物および方法 |
RU2536223C2 (ru) * | 2009-04-02 | 2014-12-20 | Вектус Байосистемс Пти Лтд | Композиции и способы для лечения фиброза аорты |
-
2006
- 2006-12-08 NZ NZ597677A patent/NZ597677A/xx unknown
- 2006-12-08 KR KR1020087016565A patent/KR101404561B1/ko active IP Right Grant
- 2006-12-08 AU AU2006322656A patent/AU2006322656B2/en active Active
- 2006-12-08 ES ES14170486.6T patent/ES2621864T3/es active Active
- 2006-12-08 CA CA2632581A patent/CA2632581C/en active Active
- 2006-12-08 RU RU2008127877/15A patent/RU2466738C2/ru active
- 2006-12-08 TW TW095145955A patent/TWI402273B/zh active
- 2006-12-08 WO PCT/AU2006/001869 patent/WO2007065226A1/en active Application Filing
- 2006-12-08 US US12/096,768 patent/US8470778B2/en active Active
- 2006-12-08 ES ES06817603.1T patent/ES2523858T3/es active Active
- 2006-12-08 EP EP14170486.6A patent/EP2783697B1/en active Active
- 2006-12-08 PT PT68176031T patent/PT1976548E/pt unknown
- 2006-12-08 NZ NZ623674A patent/NZ623674A/en unknown
- 2006-12-08 PL PL06817603T patent/PL1976548T3/pl unknown
- 2006-12-08 CA CA2952475A patent/CA2952475C/en active Active
- 2006-12-08 DK DK06817603.1T patent/DK1976548T3/da active
- 2006-12-08 CN CN2006800463844A patent/CN101325964B/zh active Active
- 2006-12-08 NZ NZ604248A patent/NZ604248A/en unknown
- 2006-12-08 JP JP2008543613A patent/JP5449778B2/ja active Active
- 2006-12-08 EP EP06817603.1A patent/EP1976548B1/en active Active
- 2006-12-08 CN CN201310356642.0A patent/CN103450345B/zh active Active
- 2006-12-08 NZ NZ569401A patent/NZ569401A/en unknown
- 2006-12-08 KR KR1020147006727A patent/KR20140041943A/ko active Search and Examination
- 2006-12-08 DK DK14170486.6T patent/DK2783697T3/en active
- 2006-12-08 BR BRPI0620566A patent/BRPI0620566B8/pt active IP Right Grant
- 2006-12-11 AR ARP060105452A patent/AR058308A1/es not_active Application Discontinuation
-
2008
- 2008-06-10 IL IL192046A patent/IL192046A/en active IP Right Grant
- 2008-07-03 ZA ZA2008/05837A patent/ZA200805837B/en unknown
-
2009
- 2009-03-26 HK HK09102915.9A patent/HK1122746A1/xx unknown
-
2012
- 2012-06-13 JP JP2012133977A patent/JP5730820B2/ja active Active
-
2013
- 2013-02-07 IL IL224609A patent/IL224609A/en active IP Right Grant
- 2013-05-28 US US13/903,227 patent/US8916523B2/en active Active
- 2013-12-26 JP JP2013269991A patent/JP5847793B2/ja active Active
-
2014
- 2014-01-19 IL IL230534A patent/IL230534A/en active IP Right Grant
- 2014-11-17 US US14/542,929 patent/US9340583B2/en active Active
-
2016
- 2016-04-19 US US15/132,475 patent/US9732136B2/en active Active
-
2017
- 2017-07-28 AR ARP170102152A patent/AR109274A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5847793B2 (ja) | Vip断片および使用の方法 | |
CA2573439C (en) | Compositions and methods for treating myocardial fibrosis comprising vasoactive intestinal peptide | |
RU2519124C2 (ru) | Композиции и способы лечения расстройств почки | |
JP5687266B2 (ja) | 大動脈線維症の治療のための組成物および方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130903 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131203 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131226 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140729 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141128 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150109 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150310 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150408 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5730820 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |